---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-25-000174"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T13:58:25.789572+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Recursion reports positive Phase 1b/2 data for REC-4881 in FAP: 75% show polyp burden reduction

## Summary
- 75% of evaluable patients reduced total polyp burden at 12 weeks; median reduction 43%.
- At 25 weeks (12 weeks off therapy), 82% maintained reduction with 53% median decrease from baseline.
- 40% of patients achieved ≥1-point improvement in Spigelman stage (upper GI disease severity).
- Safety profile consistent with MEK1/2 inhibition; no Grade ≥4 TRAEs reported to date.
- Company to engage FDA in 1H26 for registration pathway; trial expanding to ages ≥18.

## SEC filing metadata
- accession: 0001601830-25-000174
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000174/0001601830-25-000174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000174/rxrx-20251208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-25-000174
- JSON: https://secwatch.observer/filing/0001601830-25-000174.json
- Plain text: https://secwatch.observer/filing/0001601830-25-000174.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.